Adipotide (FTPP)

Adipotide, also referred to as FTPP (a fat-targeting proapoptotic peptide), is an experimental peptide studied in preclinical models for its potential to reduce white adipose tissue. Its design pairs a targeting sequence with a pro-apoptotic element intended to act selectively on the vasculature that supplies fat tissue.

Adipotide is purely experimental. It has never been approved, and there is no established human clinical use. Its profile is defined almost entirely by animal research rather than controlled human trials.

The proposed mechanism is based on animal studies and centres on targeting the blood supply of white fat. High-level themes include:

• A peptide sequence intended to home to receptors associated with the vasculature of white adipose tissue (a prohibitin-targeting approach)
• A linked pro-apoptotic element intended to trigger programmed cell death in those blood vessels
• The idea that disrupting the fat tissue's blood supply could lead to loss of fat mass

This vascular-targeting concept is distinct from metabolic peptides that act on appetite or lipid pathways. How, or whether, such a mechanism could be made safe and effective in humans remains unestablished.

Adipotide is not an approved medicine anywhere and has no recognised clinical indication. Preclinical interest focused on obesity-related endpoints, and the most cited work involved reductions in body weight in obese non-human primates.

Because it remains experimental, adipotide appears only in research discussions and, in some markets, in research-chemical listings. Any framing of it as a weight-loss treatment overstates a body of evidence that has not progressed to established human use.

As a substance not approved for human therapeutic use by any governmental regulatory health authority, adipotide falls under WADA category S0, covering unapproved substances, and would be prohibited at all times for athletes subject to anti-doping rules.

Its experimental status means it has not been the subject of well-known doping cases, but its lack of approval places it clearly within the prohibited category.

A prominent concern raised in the preclinical literature is renal toxicity, with effects on the kidneys observed in animal studies. Because the mechanism involves triggering cell death in targeted vasculature, off-target effects and organ toxicity are central safety questions rather than peripheral ones.

There is no established human safety data, no defined monitoring framework, and no approved formulation. These gaps make any real-world use difficult to evaluate for safety and place adipotide firmly in the experimental category.

Adipotide is described as a targeted peptide construct combining a homing sequence with a pro-apoptotic motif. Its pharmacology is understood mainly through animal models, where distribution to targeted tissue and organ handling are the key variables of interest.

This section describes concepts only. It intentionally does not provide doses, frequencies, or protocols, and it does not constitute medical advice.

Adipotide is not a single peptide but a two-part construct, and its full name is the clearest description of what it does: CKGGRAKDC-GG-D(KLAKLAK)₂. The first segment, CKGGRAKDC, is a homing motif isolated by in vivo phage display that binds prohibitin on the blood vessels of white fat. The second, D(KLAKLAK)₂, is a pro-apoptotic sequence built from D-amino acids that disrupts mitochondrial membranes once it is carried inside a cell. The linker "GG" simply joins them (Kolonin et al., Nature Medicine, 2004).

That architecture puts adipotide in a different category from every other compound it gets shelved beside. GLP-1 and GIP agonists such as semaglutide and tirzepatide bind receptors and change signaling — a reversible, tunable intervention. Adipotide destroys tissue. There is no meaningful sense in which the two can be "combined" or compared as alternatives, and there is no published study of adipotide alongside any other agent.

Both foundational papers came from a vascular-targeting group at the University of Texas MD Anderson Cancer Center rather than from obesity pharmacology, which is why the questions that dominate adipotide's literature — selectivity, off-target apoptosis, renal handling — are toxicology questions rather than dosing questions.

Research on adipotide is dominated by preclinical work, most notably studies in obese non-human primates that reported weight loss alongside signals of renal toxicity. This combination generated scientific interest but also underscored the safety hurdles standing between the concept and any human application.

The evidence base has not advanced to established human clinical use, so claims about adipotide as a practical fat-loss agent are not supported. High-level overviews are not a substitute for critical appraisal of the primary preclinical data.

For deeper dives on this peptide, see:

• Adipotide areas of research interest
• Adipotide side effects and safety context
• Adipotide dosing concepts (educational)
• Adipotide research and evidence overview

What does "fat-targeting" actually mean? It means the peptide homes to the blood vessels that supply white fat, not to fat cells. A phage-display screen identified the nine-amino-acid motif CKGGRAKDC as binding prohibitin, a membrane protein the authors established as a vascular marker of adipose tissue; fusing a pro-apoptotic sequence to that motif killed those vessels and ablated white fat in obese mice (Kolonin et al., Nature Medicine, 2004). Adipotide starves fat tissue rather than signaling to it — a mechanically destructive approach, which is why its safety questions are unlike those of any appetite-acting drug.

What did the monkey study actually show? It is the most-cited result and it is genuinely striking. In obese Old World monkeys, adipotide induced targeted apoptosis in white-fat blood vessels and produced rapid weight loss and improved insulin resistance, with MRI and DXA confirming a marked reduction in white adipose tissue (Barnhart et al., Science Translational Medicine, 2011). The same abstract reports the other half: "at experimentally determined optimal doses, monkeys from three different species displayed predictable and reversible changes in renal proximal tubule function." The kidney signal was not an incidental footnote — it appeared at the doses the investigators had selected as optimal.

How serious is the kidney finding? The authors described the renal proximal tubule changes as dose-dependent and reversible, which is a more favorable framing than "kidney damage," but it is also the reason the compound is discussed in terms of a therapeutic window rather than a dose. A drug whose entire mechanism is killing blood vessels lives or dies on selectivity, and the kidney is where selectivity visibly failed in the best-resourced animal study ever run on it.

Have there been human trials? No results have been published, and no study of adipotide is registered on ClinicalTrials.gov (searched August 2026). The 2011 primate paper positioned adipotide as a "prototype in a new class of candidate drugs" — and more than a decade later the class still has no candidate in registered human testing. That gap, not the animal efficacy, is the defining fact about this compound.

How does it compare with GLP-1 weight-loss drugs? They share nothing but an endpoint. Semaglutide and tirzepatide are approved medicines that bind incretin receptors to alter appetite and glucose handling, with large published phase 3 programs and reversible effects. Adipotide is an unapproved peptidomimetic that kills adipose vasculature, has no human data, and carries a documented organ-toxicity signal from its primate work. Marketing that files them under the same "fat loss" heading is flattening a difference that matters more than the similarity.